Table 1. Patient characteristics.
| IMRT (n = 68) | cRT (n = 68) | p-value | |
|---|---|---|---|
| Characteristics | No. (%) | No. (%) | |
| Age | Median 55 years | 0.49 | |
| ≤ 55 | 38 (55.9) | 33 (48.5) | |
| > 55 | 30 (44.1) | 35 (51.5) | |
| Cancer type | 0.19 | ||
| Uterine cervix | 48 (70.6) | 57 (83.8) | |
| Endometrial | 18 (26.5) | 9 (13.2) | |
| Bladder | 2 (2.9) | 2 (2.9) | |
| ECOG performance | 0.77 | ||
| 0 | 21 (30.9) | 18 (26.5) | |
| 1 | 41 (60.3) | 43 (63.2) | |
| 2 | 6 (8.8) | 7 (10.3) | |
| Stage | 0.74 | ||
| I-II | 62 (91.2) | 59 (86.7) | |
| III-IV | 6 (8.8) | 9 (13.2) | |
| Histology | 0.43 | ||
| Sqaumous ca. | 32 (47.1) | 40 (58.8) | |
| Adenoca. | 25 (36.8) | 19 (27.9) | |
| Others | 11 (16.2) | 9 (13.2) | |
| Pre-RT surgery | 0.51 | ||
| No | 11 (16.2) | 15 (22.1) | |
| Yes | 57 (83.8) | 53 (77.9) | |
| Pre-RT chemotherapy | 0.83 | ||
| No | 54 (79.4) | 56 (82.4) | |
| Yes | 14 (20.6) | 12 (17.6) | |
| Concurrent Chemotherapy | 0.23 | ||
| No (RT alone) | 36 (52.9) | 28 (41.2) | |
| Yes | 32 (47.1) | 40 (58.8) | |
| RT dose | 0.24 | ||
| < 50.4 Gy | 18 (26.5) | 11 (16.2) | |
| 50.4 Gy | 42 (61.8) | 44 (64.7) | |
| > 50.4 Gy | 8 (11.8) | 13 (19.1) | |
| RT field | 0.93 | ||
| Routine pelvis | 66 (98.5) | 67 (98.5) | |
| Extended field | 1 (1.5) | 1 (1.5) | |
| RT boost | 0.85 | ||
| No | 49 (72.1) | 48 (70.6) | |
| Yes | 19 (27.9) | 20 (29.4) | |